I just realized that in the Biomedtracker database that Van Leewenhoek used for the success rates from phase 3 to FDA approval none of those drugs would have their futility analysis included included in the data because the data start from the beginning of their phase 3 trials.

Therefore, the Van Leewenhoek choice of 55% is comparable to the data base in the sense that all trials in the database would have been pre FAs.

The phase 3 LOAs for all trials and diseases was 49.6% and for CVD it was 47% (although it is difficult to read the graph). So for whatever reason VL favours apabetalone by 7% points vs the average. That is difficult to explain given the lack of 3 point MACE data in earlier phases.

Not from what I could make out from the graph oncology has a 33% LOA from phase 3.

GAC I don't understand why Don might want the share priced supressed intentionally? I'm missing something on that one. Do you think they might have a preferred buyer. Hepalink is boxed in to some degree at 43% and 45% with warrants. They can't move up much unless they buy the company and that will cost them money. Does Don want a low share price so that someone can get a huge share of the company at a low price to fund the trials?

Being long I'm still hoping for the "BIG" payout somewhere down the line and then sitting back and watching royalties flow into Zen Cap.     :)

GLTA

Toinv